The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Therapeutics Development Initiative, 2012Lead Optimization for a Parkinson's Disease Therapeutic
Objective/Rationale:
CuII(atsm) has the potential to delay disease progression in Parkinson’s disease, based on extensive pre-clinical model data. CuII(atsm) has been shown to significantly improve... -
Target Validation, 2012DLN-101 for the Treatment of Parkinson’s DiseaseObjective/Rationale: Dln101 is a novel protein from the ghrelin family. Dln101 has several clinical and commercial advantages over ghrelin, which make it a more attractive drug target. In previous...
-
Novel Approaches to Drug Discovery, 2012Optimizing Metalloporphryins for Clinical Development Supplement 2
Promising Outcomes of Original Grant:
A newly developed glyoxylate series of metalloporphyrin compounds designed to penetrate the blood brain barrier have shown high potencies as antioxidants. A recent... -
Repositioning Drugs for PD, 2012Improving Levodopa Bioavailability and Consistency of Absorption through Co-administration of GSK962040
Objective/Rationale:
Parkinson’s disease (PD) often results in slower than normal emptying of food and medications from the stomach. This delayed gastric emptying is estimated to affect 50-90 percent... -
MJFF Research Grant, 2012Regulated GDNF Gene Therapy: A Novel Regulatory System Based on Protein Degradation
Promising Outcomes of Original Grant:
We have developed lentiviral vectors that can express functional GDNF both in the cell culture dish and in the brain of pre-clinical models. These vectors can be... -
Rapid Response Innovation Awards, 2012Ceruloplasmin Deamidation in Parkinson’s Disease Cerebrospinal Fluid: Gain of Pro-adhesive Function
Objective/Rationale:
We demonstrated that Ceruloplasmin (Cp), an enzyme present in cerebrospinal fluid (CSF), is oxidized in the CSF of PD patients. Among oxidative modifications, the asparagine...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.